Patents by Inventor Wayne A. Marasco

Wayne A. Marasco has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AFFINITY MATURED ANTI-CCR4 HUMANIZED MONOCLONAL ANTIBODIES AND METHODS OF USE
    Publication number: 20180094064
    Abstract: The present invention provides affinity matured humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from mAb 1567 and recognizes the same epitope. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.
    Type: Application
    Filed: January 27, 2017
    Publication date: April 5, 2018
    Inventors: Wayne A. Marasco, Jianhua Sui, Quan Zhu, De-Kuan Chang, Thomas S. Kupper
  • CARBONIC ANHYDRASE IX (G250) ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20180072813
    Abstract: The invention provides scFv antibodies and monoclonal antibodies that bind to and decrease an activity of Carbonic Anhydrase IX (G250). Also provided are the methods of treating and/or preventing cancer, such as renal clear cell cancer. Also provided are methods of identifying a carbonic anhydrase IX (G250) protein. The invention additionally provides methods of modifying immune effector cells, and the immune effector cells modified thereby.
    Type: Application
    Filed: May 9, 2017
    Publication date: March 15, 2018
    Inventors: Wayne A. MARASCO, Agnes LO, Chen XU, Quan Zhu
  • CARBONIC ANHYDRASE IX SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF
    Publication number: 20180030147
    Abstract: The present invention provides chimeric antigen receptor cells specific for carbonic anhydrase IX (CAIX) and methods of using same for treatment of CAIX expressing cancers such as renal cell carcinoma.
    Type: Application
    Filed: December 21, 2015
    Publication date: February 1, 2018
    Inventor: Wayne A. MARASCO
  • CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF
    Publication number: 20170362297
    Abstract: The present invention provides chimeric antigen receptors, cells expressing same and methods of using same for treatment various disorders such as cancer.
    Type: Application
    Filed: December 21, 2015
    Publication date: December 21, 2017
    Inventor: Wayne A. MARASCO
  • Human monoclonal anti-PD-L1 antibodies and methods of use
    Patent number: 9828434
    Abstract: The present invention comprises human monoclonal antibodies that bind to PD-L1 (also known as programmed death ligand 1 or B7H1). Binding of the invented antibody to PD-L1 inhibits binding to its receptor, PD1 (programmed death 1), and ligand-mediated activities and can be used to treat cancer and chronic viral infections.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: November 28, 2017
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Wayne A. Marasco, Jianhua Sui
  • Flavivirus neutralizing antibodies and methods of use thereof
    Patent number: 9822166
    Abstract: The present invention provides antibodies that neutralize flavivirus and methods of use thereof. These antibodies are derived from mAb1 1 which recognizes West Nile virus E protein and is cross-reactive with members of the flavivirus family, including Denge virus. The antibodies of the present invention prevent antibody-dependent enhancement of a viral infection by having a modified Fc region that does not bind to the Fcy receptor. The invented antibody is used to treat flaviviral infections and symptoms thereof.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 21, 2017
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventor: Wayne A. Marasco
  • GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20170304444
    Abstract: The present invention comprises human monoclonal antibodies that bind to GITR (also known as glucocorticoid-induced tumor necrosis factor receptor). Binding of the invented antibody to GITR inhibits binding of its ligand, GITR-L, and can be used to treat cancer.
    Type: Application
    Filed: October 5, 2015
    Publication date: October 26, 2017
    Inventors: Wayne A. MARASCO, Chen XU, De-Kuan CHANG
  • HUMANIZED CC CHEMOKINE RECEPTOR 4 (CCR4) ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20170290911
    Abstract: The present invention provides humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from CCR4-IgG1 and recognizes the same epitope. This antibody contains either an IgG4 or a stabilized IgG4 in order to improve binding efficiency and reduce in vivo Fab arm exchange. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer.
    Type: Application
    Filed: October 6, 2015
    Publication date: October 12, 2017
    Inventors: Wayne A. MARASCO, Quan ZHU, De-Kuan CHANG
  • IMMUNOGENETIC RESTRICTION ON ELICITATION OF ANTIBODIES
    Publication number: 20170174751
    Abstract: The present invention provides structural determinants important for binding to the stem domain of the HA protein of influenza virus, and methods of use thereof for production of high affinity neutralizing influenza virus antibodies based upon these determinants. The present invention further provides tools for determining the efficacy of an influenza virus vaccine. The present invention further provides a molecular signature useful for determining the efficacy of an influenza virus vaccine in a subject, or for predicting prior immunologic exposure or antigen responsiveness to vaccine or influenza virus infection.
    Type: Application
    Filed: March 19, 2015
    Publication date: June 22, 2017
    Inventors: Wayne Marasco, Yuval Avnir
  • Chimeric T cell receptor comprising carbonic anhydrase IX (G250) antibody
    Patent number: 9676867
    Abstract: The invention provides scFv antibodies and monoclonal antibodies that bind to and decrease an activity of Carbonic Anhydrase IX (G250). Also provided are methods of treating and/or preventing cancer, such as renal clear cell cancer. Also provided are methods of identifying a carbonic anhydrase IX (G250) protein. The invention additionally provides methods of modifying immune effector cells, and the immune effector cells modified thereby.
    Type: Grant
    Filed: May 8, 2013
    Date of Patent: June 13, 2017
    Assignee: Dana-Farber Cancer Institute Inc.
    Inventors: Wayne A. Marasco, Agnes Lo, Chen Xu
  • MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20170158752
    Abstract: The present invention provides antibodies that neutralize MERS-CoV and methods of use thereof. The invented antibody is used to treat MERS-CoV infections and symptoms thereof.
    Type: Application
    Filed: April 27, 2015
    Publication date: June 8, 2017
    Inventors: Wayne A. MARASCO, Xiangchun TANG
  • Humanized Monoclonal Antibodies and Methodsof Use
    Publication number: 20170073431
    Abstract: The present invention comprises a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene VH1-69. This antibody is derived from Mab G6 and recognizes the same epitope. Moreover, the antibody is used in combination with vaccines to augment an immune response to the antigen.
    Type: Application
    Filed: November 11, 2016
    Publication date: March 16, 2017
    Inventors: Wayne A. Marasco, Jianhua Sui, Yuval Avnir
  • Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
    Patent number: 9587028
    Abstract: The present invention provides affinity matured humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from mAb 1567 and recognizes the same epitope. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: March 7, 2017
    Assignees: Dana-Farber Cancer Institute, Inc., Brigham and Women's Hospital
    Inventors: Wayne A. Marasco, Jianhua Sui, Quan Zhu, De-Kuan Chang, Thomas S. Kupper
  • HUMANIZED MONOCLONAL ANTIBODIES AND METHODS OF USE
    Publication number: 20170044262
    Abstract: The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor CCR4. This antibody is derived from Mab 1567 and recognizes the same epitope. Binding of the invented antibody to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.
    Type: Application
    Filed: August 12, 2016
    Publication date: February 16, 2017
    Inventors: Wayne Marasco, Jianhua Sui, Quan Zhu, Thomas Kupper
  • Humanized monoclonal antibodies and methods of use
    Patent number: 9527924
    Abstract: Disclosed is a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene VHI-69. The antibody is derived from Mab G6 and recognizes the same epitope. Moreover, the antibody is used in combination with vaccines to augment an immune response to the antigen.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: December 27, 2016
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Wayne A. Marasco, Jianhua Sui, Yuval Avnir
  • USES AND ISOLATION OF VERY SMALL EMBRYONIC-LIKE (VSEL) STEM CELLS
    Publication number: 20160263163
    Abstract: The presently disclosed subject matter provides populations of stem cells that are purified from bone marrow, peripheral blood, and/or other sources. Also provided are methods of using the stem cells for treating tissue and/or organ damage in a subject.
    Type: Application
    Filed: September 3, 2015
    Publication date: September 15, 2016
    Inventors: MARIUSZ RATAJCZAK, MAGDALENA KUCIA, JANINA RATAJCZAK, DENIS RODGERSON, GEORGE SMITH, RONALD ALLEN, WAYNE MARASCO, ROBERTO BOLLI
  • Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
    Patent number: 9441045
    Abstract: The present invention provides affinity matured humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from mAb 1567 and recognizes the same epitope. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: September 13, 2016
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital
    Inventors: Wayne A. Marasco, Jianhua Sui, Quan Zhu, De-Kuan Chang, Thomas S. Kupper
  • Humanized monoclonal antibodies and methods of use
    Patent number: 9416169
    Abstract: The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor CCR4. This antibody is derived from Mab 1567 and recognizes the same epitope. Binding of the invented antibody to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: August 16, 2016
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital
    Inventors: Wayne Marasco, Jianhua Sui, Quan Zhu, Thomas Kupper
  • AFFINITY MATURED ANTI-CCR4 HUMANIZED MONOCLONAL ANTIBODIES AND METHODS OF USE
    Publication number: 20160185865
    Abstract: The present invention provides affinity matured humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from mAb 1567 and recognizes the same epitope. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.
    Type: Application
    Filed: August 7, 2015
    Publication date: June 30, 2016
    Inventors: Wayne A. Marasco, Jianhua Sui, Quan Zhu, De-Kuan Chang, Thomas S. Kupper
  • HUMANIZED MONOCLONAL ANTIBODIES AND METHODS OF USE
    Publication number: 20160176985
    Abstract: The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor CCR4. This antibody is derived from Mab 1567 and recognizes the same epitope. Binding of the invented antibody to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.
    Type: Application
    Filed: January 14, 2015
    Publication date: June 23, 2016
    Inventors: Wayne MARASCO, Jianhua Sui, Quan Zhu, Thomas Kupper